[The plant anticoagulants with perspective to use in treatment of thrombosis]

Related Experiment Video

Updated: May 8, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Izabela Pawlaczyk1, Marta Tsirigotis-Maniecka, Leszek Czerchawski

  • 1Wojewódzki Szpital Specjalistyczny we Wrocławiu, Ośrodek Badawczo-Rozwojowy. izabela.pawlaczyk@pwr.wroc.pl

Przeglad Lekarski
|September 6, 2013
PubMed

Insights

Cardiovascular diseases are a major global health issue. Research into plant-derived polyphenolic-polysaccharide conjugates shows promise for developing novel anticoagulant and anti-platelet therapies with fewer side effects.

Area of Science:

  • Pharmacology
  • Natural Products Chemistry
  • Cardiovascular Medicine

Context:

  • Cardiovascular diseases represent a leading cause of mortality, particularly in low and middle-income countries.
  • There is an ongoing global search for novel anticoagulant and anti-platelet agents with improved efficacy and reduced side effects.
  • Medicinal plants are recognized as a valuable source for discovering new therapeutic compounds.

Purpose:

  • To investigate the potential of polyphenolic-polysaccharide plant conjugates as novel therapeutic agents for cardiovascular diseases.
  • To isolate, characterize the structure, and evaluate the biological activity of these macromolecular compounds from Polish medicinal plants.

Summary:

  • This research focuses on polyphenolic-polysaccharide conjugates isolated from popular Polish medicinal plants.
  • The study details the isolation, structural characterization, and assessment of the biological activities of these compounds.
  • The isolated plant structures exhibit significant anticoagulant, antioxidant, and anti-platelet properties.

Impact:

  • These findings highlight the potential of plant-derived polyphenolic-polysaccharide conjugates as a new source for innovative cardiovascular therapeutics.
  • The research contributes to the development of novel agents that could aid in the prophylaxis and treatment of cardiovascular diseases.
  • This work supports the ongoing efforts within the WROVASC project to advance cardiovascular medicine through natural product research.

More Related Videos

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...